A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants
Status:
Completed
Trial end date:
2017-11-09
Target enrollment:
Participant gender:
Summary
This study evaluates a new formulation of insulin lispro, LY900014, a drug that lowers blood
sugar. It is administered by injection into the vein and under the skin of the abdomen, thigh
and arm.
The study will be conducted in healthy people to investigate the effect of different
injection sites on the amount of insulin lispro in the bloodstream.
Side effects and tolerability will be documented. The study will last for about 10 weeks for
each participant, including screening and follow up. Screening is required within 28 days
prior to entering the study.